Gleason grading controversies: What the Chemoprevention trials have taught us

Journal of the Canadian Urological Association

Volumn 3, Issue 3 SUPPL. 2, 2009, Pages

  Klotz, Laurence ^a   Drachenberg, Darrel ^b   Fradet, Yves ^c   Saad, Fred ^d   Trachtenberg, John ^e   Zlotta, Alexandre ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72049129413     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Hudson RW. Comparison of nuclear 5 alpha-reductase activities in the stromal and epithelial fractions of human prostatic tissue. J Steroid Biochem 1987; 26 (3): 349-353.
2. Iehle C, Radvanyi F, Gil Diez dM, et al. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999; 68 (5-6): 189-195.
3. Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 2008; 53 (2): 244-252.
4. Brawer MK. The evolution of hormonal therapy for prostatic carcinoma. Rev Urol 2001; 3 Suppl 3: S1-S9.
5. Whittemore AS, Wu AH, Kolonel LN, et al. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 1995; 141 (8): 732-740.
6. Brawley OW, Barnes ST. Potential agents for prostate cancer chemoprevention. Epidemiol Rev 2001; 23 (1): 168-172.
7. The Alpha-Tocopherol BCCPSG. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330 (15): 1029-1035.
8. Clark LC, Combs GF, Jr., Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996; 276 (24): 1957-1963.
9. Klein EA, Thompson IM, Lippman SM, et al. SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design. Prostate Cancer Prostatic Dis 2000; 3 (3): 145-151.
10. Tsukamoto S, Akaza H, Onozawa M, Shirai T, Ideyama Y. A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer 1998; 82 (3): 531-537.
11. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349 (3): 215-224.
12. Thompson IM. Chemoprevention of prostate cancer: agents and study designs. J Urol 2007; 178 (3 Pt 2): S9-S13.
13. Musquera M, Fleshner NE, Finelli A, Zlotta AR. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Expert Rev Anticancer Ther 2008; 8 (7): 1073-1079.
14. Yang XJ, Lecksell K, Short K, et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1999; 53 (4): 696-700.
15. Carver BS, Kattan MW, Scardino PT, Eastham JA. Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU Int 2005; 95 (4): 509-512.
16. Schatzl G, Madersbacher S, Haitel A, et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 2003; 169 (4): 1312-1315.
17. Melia J, Moseley R, Ball RY, et al. A UK-based investigation of inter- and intra-observer reproducibility of Gleason grading of prostatic biopsies. Histopathology 2006; 48 (6): 644-654.
18. Norberg M, Egevad L, Holmberg L, Sparen P, Norlen BJ, Busch C. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 1997; 50 (4): 562-566.
19. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99 (18): 1375-1383.
20. Cohen YC, Liu KS, Heyden NL, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99 (18): 1366-1374.
21. Kulkarni GS, Al Azab R, Lockwood G, et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 2006; 175 (2): 505-509.
22. Pinsky P, Parnes H, Ford L. Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev. Res.: 10. 1158/1940-6207. CAPR-07-0007.
23. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271 (5): 368-374.
24. Lucia MS, Darke AK, Goodman FG, et al. "Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention". Cancer Prev. Res.: 10. 1158/1940-6207. CAPR-08-0078.
25. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98 (16): 1128-1133.
26. Redman MW, Tangen CM, Goodman MS, Lucia CA, Coltman CA, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: A bia-adjusted modeling approach. Cancer Prev. Res.: 10. 1158/1940-6207. CAPR-08-0092.
27. Fleshner N, Gomella LG, Cookson MS, et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials 2007; 28 (6): 763-769.
28. Makridakis NM, di SE, Reichardt JK. Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics 2000; 10 (5): 407-413.
29. Salam MT, Ursin G, Skinner EC, Dessissa T, Reichardt JK. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol 2005; 23 (4): 246-253.
30. Cussenot O, Azzouzi AR, Nicolaiew N, et al. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. Eur Urol 2007; 52 (4): 1082-1087.
31. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006; 296 (13): 1619-1632.
32. Christen WG, Gaziano JM, Hennekens CH. Design of Physicians' Health Study II-a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol 2000; 10 (2): 125-134.